Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 03 Sep 2022
Pfizer/BioNTech bivalent COVID-19 booster approved by UK medicines regulator
3 September 2022 - The adapted COVID-19 vaccine targets both the original virus and the Omicron variant. ...
Posted by Michael Wonder on 03 Sep 2022
ATAGI update following weekly COVID-19 meeting (31 August 2022)
2 September 2022 - An update from the Australian Technical Advisory Group on Immunisation following their weekly meeting on 31 August ...
Posted by Michael Wonder on 03 Sep 2022
Every life is worth the same, but maybe not at PHARMAC
4 September 2022 - One of the dubious consequences of our obsession with race is the collection of data on ...
Posted by Michael Wonder on 03 Sep 2022
Swissmedic authorises Novavax Nuvaxovid COVID-19 vaccine for adolescents aged 12 through 17 and as a booster in adults aged 18 and older
2 September 2022 - Novavax today announced that Swissmedic has expanded its temporary authorisation of Nuvaxovid COVID-19 vaccine in Switzerland for ...
Posted by Michael Wonder on 02 Sep 2022
The CEO of GoodRx doesn’t think mail order pharmacies are the ‘right answer’ to lowering prescription drug prices
2 September 2022 - Cartoonishly high hospital bills, overpriced prescription drugs, crowdsourcing for medical treatments—these are all features of the US ...
Posted by Michael Wonder on 02 Sep 2022
FDA still skeptical of ALS drug ahead of high stakes meeting
3 September 2022 - The U.S. FDA has posted another negative review of a closely watched drug for the deadly neurodegenerative ...
Posted by Michael Wonder on 02 Sep 2022
Call for Keytruda: Bay of Plenty couple needs help funding hefty cancer treatment
1 September 2022 - Tim Pardy thought he'd beat it. Five months later his pancreatic cancer not only returned, but it ...
Posted by Michael Wonder on 02 Sep 2022
Bayer’s Keredia (finerenone) receives updated label to include findings from Phase 3 FIGARO-DKD cardiovascular outcomes study in patients with chronic kidney disease and type 2 diabetes
1 September 2022 - US label now inclusive of data from comprehensive Phase 3 clinical trial program (FIGARO-DKD and FIDELIO-DKD) investigating ...
Posted by Michael Wonder on 02 Sep 2022
Vertex announces U.S. FDA approval for Orkambi (lumacaftor/ivacaftor) in children with cystic fibrosis ages 12 to <24 months
2 September 2022 - With this approval, approximately 300 children with two copies of the F508del mutation will have a ...
Posted by Michael Wonder on 02 Sep 2022
FDA approves durvalumab for locally advanced or metastatic biliary tract cancer
2 September 2022 - Today the FDA approved durvalumab (Imfinzi, AstraZeneca) in combination with gemcitabine and cisplatin for adult patients ...
Posted by Michael Wonder on 02 Sep 2022
First de novo deuterated drug poised for approval
1 September 2022 - Bristol Myers Squibb’s first in class TYK2 inhibitor and blockbuster contender deucravacitinib showcases the role for heavy ...
Posted by Michael Wonder on 02 Sep 2022
Azurity Pharmaceuticals announces FDA approval of Konvomep (omeprazole and sodium bicarbonate for oral suspension)
2 September 2022 - Azurity Pharmaceuticals announced today that the US FDA has approved Konvomep (omeprazole and sodium bicarbonate for oral ...
Posted by Michael Wonder on 02 Sep 2022
FDA approves the first treatment option for generalized pustular psoriasis flares in adults
1 September 2022 - More than half of patients treated with Spevigo (spesolimab-sbzo) injection, for intravenous use showed no visible pustules ...
Posted by Michael Wonder on 02 Sep 2022
Updated agenda for the November 2022 PBAC meeting
2 September 2022 - The agenda for the November 2022 PBAC meeting has been updated. ...
Posted by Michael Wonder on 01 Sep 2022
EMA CHMP adopts positive opinion recommending authorisation for the use of Moderna's Omicron targeting bivalent booster in the European Union
1 September 2022 - Study results show mRNA-1273.214 has demonstrated significantly higher antibody titers against Omicron BA.1 and BA.4/5 sub-variants when ...